Business Wire

Chemours Publishes 2023 Sustainability Report

11.6.2024 13:45:00 EEST | Business Wire | Press release

Share

The Chemours Company (“Chemours”) (NYSE: CC), a global chemistry company, today announced the seventh edition of its annual Sustainability Report, outlining the Company’s progress toward meeting its 2030 Corporate Responsibility Commitment (CRC) goals. The report titled “Partnering for Progress,” showcases how Chemours embraces partnerships to deliver innovative products responsibly and more sustainably, share its success with others, and drive business value.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240611034340/en/

Chemours' seventh edition of its annual Sustainability Report, outlines the Company’s progress toward meeting its 2030 Corporate Responsibility Commitment goals. The report titled “Partnering for Progress,” showcases how Chemours embraces partnerships to deliver innovative products responsibly and more sustainably, share its success with others, and drive business value. (Graphic: Business Wire)

“Chemours’ commitment to sustainability and our values is unwavering. We’ve made significant progress against our Corporate Responsibility Commitment goals, prioritizing actions that improve how people live, power modern progress, and protect our planet for future generations,” said Denise Dignam, President and CEO of Chemours. “We are focused on priorities that matter to our company, customers, and stakeholders, and we fully integrate sustainability into our business decisions and actions across our organization.”

Chemours organizes its sustainability strategy and CRC goals around four pillars: Environmental Leadership, Innovation & Sustainable Solutions, Community Impact, and Greatest Place to Work for All. Inspired by the Company’s vision, these pillars guide the daily actions and decisions of its employees, from operations and product innovation to stakeholder and community engagement.

“The modern world continues to progress faster each year, and that brings both societal challenges and opportunities for creating a more sustainable world,” said Dr. Amber Wellman, Chief Sustainability Officer of Chemours. “Climate change, nature loss, social inequality, and public health are some of the most pressing issues of our time, and they require bold, collaborative action across society. At Chemours, we believe in the power of partnerships to find the best solutions to the biggest challenges and the opportunities they offer to accelerate progress. By working together, and through the unique capabilities of our chemistry, we help enable important applications that deliver on societal goals, such as transitioning to clean energy, driving innovation in low global warming potential thermal management solutions, advancing electronics and electrifying transportation, progressing a greener and more inclusive future, and helping improve lives everywhere.”

Chemours’ 2023 Sustainability Report highlights include:

  • Achieved a 52% reduction in operational greenhouse gas (GHG) emissions since 2018—on track for a 60% reduction by 2030.
  • Reached a 59% reduction in total process fluorinated organic chemical (FOC) emissions to air and water since 2018—on our way to a 99% or more reduction by 2030.
  • Met and surpassed our Sustainable Supply Chain goal, assessing the sustainability performance of 81% of suppliers by spend, with 24% demonstrating improvement in sustainability performance. Additionally, 85% of Chemours’ supplier partners scored above the average threshold of all companies rated by EcoVadis.
  • Developed a framework with the Wildlife Habitat Council to conduct a nature assessment and implement a corporate-wide, nature-based initiative in 2024.
  • Invested $3 million in the Center for Clean Hydrogen as part of the Clean Hydrogen Partnership, which will work to solve the challenges of creating low-cost clean hydrogen and efficient hydrogen energy conversion.
  • Expanded ChemFEST, our middle school STEM education partnership program, at five sites in the U.S. and Belgium.
  • Earned Great Place to Work® Certification in 15 global regions, covering more than 92% of Chemours’ global workforce.

Strong partnerships are essential to making progress. Learn more about how Chemours’ partners are helping strengthen environmental stewardship and social responsibility in the 2023 Sustainability Report.

About The Chemours Company

The Chemours Company (NYSE: CC) is a global leader in Titanium Technologies, Thermal & Specialized Solutions, and Advanced Performance Materials providing its customers with solutions in a wide range of industries with market-defining products, application expertise and chemistry-based innovations. We deliver customized solutions with a wide range of industrial and specialty chemicals products for markets, including coatings, plastics, refrigeration and air conditioning, transportation, semiconductor and consumer electronics, general industrial, and oil and gas. Our flagship products are sold under prominent brands such as Ti-Pure™, Opteon™, Freon™, Teflon™, Viton™, Nafion™, and Krytox™. The Company has approximately 6,200 employees and 28 manufacturing sites, and serves approximately 2,700 customers in approximately 110 countries. Chemours is headquartered in Wilmington, Delaware and is listed on the NYSE under the symbol CC.

For more information, we invite you to visit chemours.com or follow us on X (formerly Twitter) @Chemours or on LinkedIn.

Forward-Looking Statements

This press release contains forward-looking statements, within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, which involve risks and uncertainties. Forward-looking statements provide current expectations of future events based on certain assumptions and include any statement that does not directly relate to a historical or current fact. The words "believe," "expect," "will," "anticipate," "plan," "estimate," "target," "project" and similar expressions, among others, generally identify "forward-looking statements," which speak only as of the date such statements were made. These forward-looking statements may address, among other things, our progress against our Corporate Responsibility Commitment goals and our expected positive impact on societal goals, all of which are subject to substantial risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. Forward-looking statements are based on certain assumptions and expectations of future events that may not be accurate or realized, such as full year guidance relying on models based upon management assumptions regarding future events that are inherently uncertain. These statements are not guarantees of future performance. Forward-looking statements also involve risks and uncertainties that are beyond Chemours' control. Matters outside our control, including general economic conditions, geopolitical conditions and global health events and weather events, have affected or may affect our business and operations and may or may continue to hinder our ability to provide goods and services to customers, cause disruptions in our supply chains such as through strikes, labor disruptions or other events, adversely affect our business partners, significantly reduce the demand for our products, adversely affect the health and welfare of our personnel or cause other unpredictable events. Additionally, there may be other risks and uncertainties that Chemours is unable to identify at this time or that Chemours does not currently expect to have a material impact on its business. Factors that could cause or contribute to these differences include the risks, uncertainties and other factors discussed in our filings with the U.S. Securities and Exchange Commission, including in our Annual Report on Form 10-K for the year ended December 31, 2023 and our Quarterly Report on Form 10-Q for the quarter ended March 31, 2024. Chemours assumes no obligation to revise or update any forward-looking statement for any reason, except as required by law.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240611034340/en/

Contacts

INVESTORS
Brandon Ontjes
Vice President, Investor Relations
+1.302.773.3300
investor@chemours.com

Kurt Bonner,
Manager, Investor Relations
+1.302.773.0026
investor@chemours.com

NEWS MEDIA
Cassie Olszewski
Corporate Media & Brand Reputation Leader
+1.302.219.7140
media@chemours.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Landmark Global Galderma Survey Shows 9 out of 10 People Are Affected by Skin Quality Concerns7.7.2026 08:00:00 EEST | Press release

Galderma (SWX:GALD) has unveiled results from the world’s most extensive skin quality profiling survey, finding that skin quality concerns are widespread, can impact emotional wellbeing and, while differing based on the individual, are often similar among people alike in age, lifestyle, and environment.1 These results underscore the need for effective solutions that can be tailored to a wide variety of skin quality concerns. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260706426842/en/ Key findings:1 Nine out of ten people globally are affected by skin quality concerns, with each person experiencing an average of two concerns in the past month The most common concerns are fine lines and wrinkles (41%), dry skin (40%), and dull skin (37%), most frequently affecting the face Skin quality impacts quality of life for 85% of people, with more than one in three reporting feelings of self-consciousness, insecurity or anxiety Skin

Morinaga Milk Achieves Self-Affirmed GRAS Status for LAC-Living+™, Expanding U.S. Opportunities for Its Postbiotic Ingredient7.7.2026 05:00:00 EEST | Press release

Morinaga Milk Industry Co., Ltd. (TOKYO:2264), a leading Japanese dairy and functional ingredient company, today announced that it has achieved self-affirmed GRAS (Generally Recognized As Safe) status in the United States for LAC-Living+™ (L. helveticus MCC1848), its proprietary postbiotic ingredient. This milestone expands the commercial availability of LAC-Living+ in the U.S. market and enables its use in dietary supplements, functional foods, and beverages, supporting the development of products designed to address growing consumer demand for health and well-being solutions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260706806943/en/ Growing Interest in Postbiotics and Mental Well-Being Consumer interest in proactive health management has expanded significantly in recent years, alongside increasing awareness of the connection between the gut and the brain, commonly referred to as the gut–brain axis. As a result, the g

Access Advance Welcomes New Licensors to the Video Distribution Patent Pool7.7.2026 03:00:00 EEST | Press release

Access Advance LLC today announced that Sharp, M&K Holdings, Tagivan and 9 other patent owners who own substantial video codec patent portfolios that cover the core technologies behind video decoding, processing, and streaming media delivery, have joined the Video Distribution Patent Pool (VDP Pool) in the first half of 2026. "The addition of all of these new Licensors’ patent portfolios is a real win for both the VDP Pool and our many existing and future Licensees,” said Peter Moller, CEO of Access Advance. “These companies have broad and deep patent portfolios and further enhance the program’s market leading position in resolving the licensing issues around the use of modern video codecs across all the diverse business models of internet video streaming.” The following patent holders have joined the VDP Pool as Licensors in the first half of 2026: Digital Insights Inc. Hanbat National University Industry-Academic Cooperation Foundation Hanwha Vision Co., Ltd. Industry-Academy Coopera

Real Chemistry Announces New Asia Pacific Hub with Acquisition of Spurwing Communications in Singapore7.7.2026 02:00:00 EEST | Press release

Real Chemistry, a global leader in AI- and insights-driven healthcare communications, today announced the acquisition of Spurwing Communications, establishing the company’s first Asia Pacific (APAC) strategic hub in Singapore. This milestone strengthens Real Chemistry’s global strategy and presence in APAC, enhancing its ability to support healthcare organizations. Combining deep market expertise with globally integrated capabilities across analytics, medical communications, advertising and strategic communications, the company is well positioned to deliver more connected, local insight-driven support — ultimately helping clients better reach and engage healthcare professionals, patients and caregivers across the region. “APAC is fast becoming one of the most dynamic and strategically important regions for healthcare innovation and access to life-improving therapies,” said Kath Harrison, Group President, International Growth at Real Chemistry. “By bringing Spurwing into Real Chemistry,

Vertex to Acquire Crinetics Pharmaceuticals6.7.2026 23:04:00 EEST | Press release

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) and Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a global pharmaceutical company focused on the discovery, development and commercialization of novel therapeutics for endocrine diseases, today announced that the companies have entered into a definitive agreement under which Vertex will acquire Crinetics for $85.00 per share in cash, for a total equity value of approximately $10.0 billion, or approximately $8.8 billion net of estimated cash acquired. The transaction was unanimously approved by both the Vertex and Crinetics Boards of Directors and is anticipated to close in the third quarter of 2026. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260706876183/en/ Crinetics’ marketed medicine, PALSONIFY® (paltusotine), received approval from the U.S. Food and Drug Administration (FDA) in September 2025. PALSONIFY was recently approved by the European Medicines Agency (EMA) a

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye